Published in Assay Drug Dev Technol on August 01, 2010
Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol Sci (2013) 1.29
High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines. Assay Drug Dev Technol (2013) 0.91
The p53-MDM2/MDMX axis - A chemotype perspective. Medchemcomm (2011) 0.88
Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem (2014) 0.85
HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines. Assay Drug Dev Technol (2015) 0.80
High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions. Assay Drug Dev Technol (2014) 0.77
Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC Screen. Assay Drug Dev Technol (2016) 0.75
Surfing the p53 network. Nature (2000) 35.36
A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen (1999) 32.67
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Cell-cycle checkpoints and cancer. Nature (2004) 13.19
The p53-mdm-2 autoregulatory feedback loop. Genes Dev (1993) 11.19
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 9.48
Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev (2004) 9.28
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A (2006) 4.68
Pharmacological rescue of mutant p53 conformation and function. Science (1999) 3.91
Visualization of molecular interactions by fluorescence complementation. Nat Rev Mol Cell Biol (2006) 3.79
Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol (2002) 3.45
p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol (2005) 2.78
Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol (2006) 2.75
Living with p53, dying of p53. Cell (2007) 2.62
Dissecting p53-dependent apoptosis. Cell Death Differ (2006) 2.44
MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem (2006) 2.20
Universal strategies in research and drug discovery based on protein-fragment complementation assays. Nat Rev Drug Discov (2007) 2.20
Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol (2002) 2.03
Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem (2006) 1.91
Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res (2007) 1.76
Universal screening methods and applications of ThermoFluor. J Biomol Screen (2006) 1.69
Molecular and cellular approaches for the detection of protein-protein interactions: latest techniques and current limitations. Plant J (2008) 1.62
MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol (2007) 1.59
p53 Activation by small molecules: application in oncology. J Med Chem (2005) 1.55
Restoration of p53 to limit tumor growth. Curr Opin Oncol (2008) 1.52
Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene (2002) 1.51
HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev Technol (2007) 1.40
Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med (Berl) (2007) 1.40
Control of cell migration: a tumour suppressor function for p53? Biol Cell (2006) 1.39
Emerging classes of protein-protein interaction inhibitors and new tools for their development. Curr Opin Chem Biol (2004) 1.38
Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis. Cytometry A (2005) 1.31
Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol (2003) 1.25
Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ (2006) 1.23
Protein biosensors based on the principle of fluorescence resonance energy transfer for monitoring cellular dynamics. Biotechnol Lett (2006) 1.18
Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Assay Drug Dev Technol (2008) 1.14
Rescue of mutant p53 transcription function by ellipticine. Oncogene (2003) 1.14
Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation. Cell Cycle (2008) 1.08
Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors. Assay Drug Dev Technol (2007) 1.07
Fluorescent-protein biosensors: new tools for drug discovery. Trends Biotechnol (1998) 1.05
Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol Ther (2005) 1.02
Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library. Assay Drug Dev Technol (2009) 1.02
Development and optimization of high-throughput in vitro protein phosphatase screening assays. Nat Protoc (2007) 1.01
Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. Mol Pharmacol (1998) 1.01
Mammalian two-hybrids come of age. Trends Biochem Sci (2009) 1.01
Requirements, features, and performance of high content screening platforms. Methods Mol Biol (2007) 0.95
Generation and characterization of a stable MK2-EGFP cell line and subsequent development of a high-content imaging assay on the Cellomics ArrayScan platform to screen for p38 mitogen-activated protein kinase inhibitors. Methods Enzymol (2006) 0.93
CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73. J Biol Chem (2004) 0.93
High-throughput screening assays to discover small-molecule inhibitors of protein interactions. Curr Drug Discov Technol (2008) 0.90
Assay development and case history of a 32K-biased library high-content MK2-EGFP translocation screen to identify p38 mitogen-activated protein kinase inhibitors on the ArrayScan 3.1 imaging platform. Methods Enzymol (2006) 0.88
A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization. Apoptosis (2008) 0.87
Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation. Methods Enzymol (2006) 0.86
Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis. J Pharmacol Sci (2007) 0.85
P53 and p38 MAPK pathways are involved in MONCPT-induced cell cycle G2/M arrest in human non-small cell lung cancer A549. J Cancer Res Clin Oncol (2009) 0.79
A simple cell-based HTS assay system to screen for inhibitors of p53-Hdm2 protein-protein interactions. Assay Drug Dev Technol (2006) 0.78
Chemical genetics of Plasmodium falciparum. Nature (2010) 5.52
Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene (2003) 2.57
High content screening applied to large-scale cell biology. Trends Biotechnol (2004) 2.36
microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res (2009) 2.32
Automated image-based phenotypic analysis in zebrafish embryos. Dev Dyn (2009) 2.11
Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther (2007) 1.95
Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat Chem Biol (2009) 1.88
The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem (2004) 1.75
Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. J Biol Chem (2008) 1.74
Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin α1-antitrypsin Z. PLoS One (2010) 1.62
Advances in high content screening for drug discovery. Assay Drug Dev Technol (2003) 1.55
Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res (2010) 1.54
The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol (2003) 1.44
HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev Technol (2007) 1.40
Halenaquinone and xestoquinone derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp. Bioorg Med Chem (2005) 1.40
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol (2008) 1.38
22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol Chem (2003) 1.37
Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase. J Biol Chem (2002) 1.37
Multiplexed high content screening assays create a systems cell biology approach to drug discovery. Drug Discov Today (2005) 1.36
The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. J Biol Chem (2005) 1.31
The substrate recognition domains of the N-end rule pathway. J Biol Chem (2008) 1.31
Cellular platforms for HTS: three case studies. Drug Discov Today (2002) 1.30
Diallyl trisulfide-induced G(2)-M phase cell cycle arrest in human prostate cancer cells is caused by reactive oxygen species-dependent destruction and hyperphosphorylation of Cdc 25 C. Oncogene (2005) 1.30
The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther (2005) 1.29
PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells. Cancer Res (2007) 1.28
Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J Immunother (2005) 1.25
Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta (2010) 1.25
Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility. BMC Chem Biol (2010) 1.20
Dual-specificity phosphatases as targets for antineoplastic agents. Nat Rev Drug Discov (2002) 1.19
Dual specificity protein phosphatases: therapeutic targets for cancer and Alzheimer's disease. Annu Rev Pharmacol Toxicol (2005) 1.18
Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds. ACS Chem Biol (2009) 1.18
Internet-based image analysis quantifies contractile behavior of individual fibroblasts inside model tissue. Biophys J (2003) 1.15
Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. J Med Chem (2009) 1.14
Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Assay Drug Dev Technol (2008) 1.14
Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. PLoS Negl Trop Dis (2009) 1.14
In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J Pharmacol Exp Ther (2010) 1.11
Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2. Antimicrob Agents Chemother (2005) 1.11
Identification of survival genes in human glioblastoma cells by small interfering RNA screening. Mol Pharmacol (2009) 1.11
A target-based high throughput screen yields Trypanosoma brucei hexokinase small molecule inhibitors with antiparasitic activity. PLoS Negl Trop Dis (2010) 1.10
Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments. Assay Drug Dev Technol (2010) 1.10
A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. Mol Cancer Ther (2008) 1.10
Systems cell biology based on high-content screening. Methods Enzymol (2006) 1.07
Targeted deletion of the metastasis-associated phosphatase Ptp4a3 (PRL-3) suppresses murine colon cancer. PLoS One (2013) 1.07
Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors. Assay Drug Dev Technol (2007) 1.07
Effector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity. Chem Biol (2013) 1.05
Cellular analysis of disorazole C and structure-activity relationship of analogs of the natural product. Chem Biol Drug Des (2006) 1.05
Redox regulation of Cdc25B by cell-active quinolinediones. Mol Pharmacol (2005) 1.04
Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin. Biochemistry (2005) 1.03
Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library. Assay Drug Dev Technol (2009) 1.02
Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 6-chloro-7-[corrected](2-morpholin-4-ylethylamino)-quinoline-5,8-dione. J Biol Chem (2002) 1.02
Development and optimization of high-throughput in vitro protein phosphatase screening assays. Nat Protoc (2007) 1.01
Induction of Cdc25B regulates cell cycle resumption after genotoxic stress. Cancer Res (2007) 1.01
Design, Synthesis, and Biological Evaluation of PKD Inhibitors. Pharmaceutics (2011) 0.99
NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors. J Pharmacol Exp Ther (2004) 0.99
Use of an electronic alert to identify patients with acute kidney injury. Clin Med (2014) 0.99
Cell-active dual specificity phosphatase inhibitors identified by high-content screening. Chem Biol (2003) 0.99
Hypoxia-mediated regulation of Cdc25A phosphatase by p21 and miR-21. Cell Cycle (2009) 0.98
Synthesis and Structure-Activity Relationships of Benzothienothiazepinone Inhibitors of Protein Kinase D. ACS Med Chem Lett (2011) 0.97
Synthesis and biological assessment of simplified analogues of the potent microtubule stabilizer (+)-discodermolide. Bioorg Med Chem (2003) 0.97
Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase. Mol Pharmacol (2004) 0.96
Microtubule binding and disruption and induction of premature senescence by disorazole C(1). J Pharmacol Exp Ther (2008) 0.96
Identifying actives from HTS data sets: practical approaches for the selection of an appropriate HTS data-processing method and quality control review. J Biomol Screen (2010) 0.96
Requirements, features, and performance of high content screening platforms. Methods Mol Biol (2007) 0.95
High-content screening with siRNA optimizes a cell biological approach to drug discovery: defining the role of P53 activation in the cellular response to anticancer drugs. J Biomol Screen (2004) 0.95
Designing, optimizing, and implementing high-throughput siRNA genomic screening with glioma cells for the discovery of survival genes and novel drug targets. J Neurosci Methods (2009) 0.95
Systems cell biology knowledge created from high content screening. Assay Drug Dev Technol (2005) 0.94
A scalable high-content cytotoxicity assay insensitive to changes in mitochondrial metabolic activity. Oncol Res (2004) 0.94
Development, validation and implementation of immobilized metal affinity for phosphochemicals (IMAP)-based high-throughput screening assays for low-molecular-weight compound libraries. Nat Protoc (2008) 0.94
Generation and characterization of a stable MK2-EGFP cell line and subsequent development of a high-content imaging assay on the Cellomics ArrayScan platform to screen for p38 mitogen-activated protein kinase inhibitors. Methods Enzymol (2006) 0.93
Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor. Int Immunopharmacol (2011) 0.93
Marine sesquiterpenoids that inhibit the lyase activity of DNA polymerase beta. J Nat Prod (2004) 0.93
Interleukin-1beta can mediate growth arrest and differentiation via the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. Cytokine (2004) 0.92
Strategies for discovery of small molecule radiation protectors and radiation mitigators. Front Oncol (2012) 0.92
Phosphatase of regenerating liver-1 promotes cell migration and invasion and regulates filamentous actin dynamics. J Pharmacol Exp Ther (2010) 0.92
High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines. Assay Drug Dev Technol (2013) 0.91
Analysis of the role of bleomycin hydrolase in antigen presentation and the generation of CD8 T cell responses. J Immunol (2007) 0.90